Results 71 to 80 of about 41,377 (182)

Prenatal testing and postpartum treatment for hepatitis C virus among women with opioid use disorder

Pregnancy, Volume 2, Issue 5, September 2026.
Abstract Introduction In the past decade, hepatitis C virus (HCV) infections among pregnant women increased dramatically in the United States, rising in parallel with the opioid crisis and increasing the number of children at risk for HCV. People with HCV infection that remains untreated are also at increased risk of cirrhosis, liver cancer, and death.
Lucas Gosdin, Kathryn Miele, Shin Y. Kim, Marcela C. Smid, Julie H. Shakib, Judette M. Louis, Tanner Wright, Neil S. Seligman, Carrie Irvine, Pilar M. Sanjuan, Lawrence Leeman, Michelle L. Henninger, Autumn Davidson, Elisha M. Wachman, Kara M. Rood, Anna Bartholomew, Suzanne Gilboa, Kate R. Woodworth, Van T. Tong, Lakshmi Panagiotakopoulos   +19 more
wiley   +1 more source

Antiviral Use in Mild-to-Moderate SARS-CoV-2 Infections during the Omicron Wave in Geriatric Patients

Viruses
(1) Background: Geriatric patients are at high risk of complications of Coronavirus disease-2019 (COVID-19) and are good candidates for antiviral drugs.
Nadia Exquis, Benjamin Dionisi, Caroline Flora Samer, Victoria Rollason, François Curtin, Dina Zekry, Christophe Graf, Virgnie Prendki, Kuntheavy Ing Lorenzini   +8 more
doaj   +1 more source

Exploration of Nirmatrelvir Derivatives as Optimized SARS‐CoV‐2 Antivirals

ChemMedChem, Volume 21, Issue 15, 14 August 2026.
Structure‐guided optimization of nirmatrelvir identifies aldehyde and dichloroacetamide warheads and a potency‐enhancing S4 thioamide. Crystal structures reveal an S2 rearrangement extending toward Cys44, suggesting a new covalent‐design opportunity.
Yugendar R. Alugubelli, Veerabhadra R. Vulupala, Kai S. Yang, Kaustav Khatua, Lauren R. Blankenship, Sathish Kumar, Demonta Coleman, Xuejiao Guo, Zhi Zachery Geng, Chia‐Chuan D. Cho, Banumathi Sankaran, Benjamin W. Neuman, Shiqing Xu, Wenshe Ray Liu   +13 more
wiley   +1 more source

B‐Cell Depletion Relative to Tumor Necrosis Factor Inhibition Extends the Duration of Viral Shedding in COVID‐19 Among Autoimmune Disease Patients: A Matched Prospective Cohort Study

ACR Open Rheumatology, Volume 8, Issue 8, August 2026.
Objective To investigate SARS‐CoV‐2 viral shedding duration in autoimmune patients using B cell depleting (BCD) therapy or tumor necrosis factor inhibitors (TNFi) and immunocompetent comparators. Methods We conducted a matched cohort analysis among participants in POSITIVES, a prospective study enrolling outpatients with acute COVID‐19 within five days
Liya Sisay Getachew, Xiaosong Wang, Naomi J. Patel, Zachary S. Wallace, Lauren A. O'Keeffe, Madison Negron, Jiaqi Wang, Grace Qian, Alene A. Saavedra, Kevin T. Mueller, Natalie Davis, Yijia Li, Brooke M. Leeman, Manish C. Choudhary, Sebastien Haneuse, Luke Benz, Julie Boucau, Gregory E. Edelstein, Owen T. Glover, Yumeko Kawano, Rinki Deo, Zahra Reynolds, Karry Su, Chase B. Mandell, Zoie Smith‐Sparks, Eliza Passell, Mamadou Oury Barry, Dessie Tien, Sarah P. Hammond, Gaurav D. Gaiha, Jacob E. Lemieux, Amy K. Barczak, Jonathan Z. Li, Mark J. Siedner, Jeffrey A. Sparks   +34 more
wiley   +1 more source

Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review

Advances in Respiratory Medicine
Nirmatrelvir/Ritonavir is an oral treatment for mild to moderate COVID-19 cases with a high risk for a severe course of the disease. For this paper, a comprehensive literature review was performed, leading to a summary of currently available data on ...
Sydney Paltra, Tim O. F. Conrad
doaj   +1 more source

Quantitative prediction of intravenous drug interactions caused by cytochromes P450 inhibitors and inducers

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2682-2692, August 2026.
Background Aims Pharmacokinetic interaction studies typically focus on oral administration, but intravenous (IV) administration bypasses intestinal degradation and hepatic first‐pass metabolism, leading to distinct drug–drug interaction (DDI) magnitude. This study aimed to develop a predictive model for DDIs involving IV‐administered drugs.
Vianney Tuloup, Michel Tod, Laurent Bourguignon   +2 more
wiley   +1 more source

Contraindicated drug–drug interactions and associated adverse drug reactions in an observational cohort study of 4543 paediatric hospitalized patients

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2834-2852, August 2026.
Abstract Background and Purpose Drug–drug interactions (DDIs) are associated with an increased risk of adverse drug reactions (ADRs). Hospitalized children are particularly vulnerable to DDIs and ADRs due to polypharmacy, frequent use of unlicensed or off‐label medications, and dosing regimens often extrapolated from adult data.
Emilie Laval, Sylvain Goutelle, Inesse Boussaha, Xavier Dode, Yanis Mimouni, Kim An Nguyen, Behrouz Kassai   +6 more
wiley   +1 more source

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 531-541, August 2026.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

The Development of an Oral Solution Containing Nirmatrelvir and Ritonavir and Assessment of Its Pharmacokinetics and Stability

Pharmaceutics
Paxlovid®, a co-packaged medication comprised of separate tablets containing two active ingredients, nirmatrelvir (NRV) and ritonavir (RTV), exhibits good effectiveness against coronavirus disease 2019 (COVID-19). However, the size of the NRV/RTV tablets
Lili Wang, Zhuang Ding, Zhengping Wang, Yanna Zhao, Hengqian Wu, Qipeng Wei, Lingfeng Gao, Jun Han   +7 more
doaj   +1 more source

Differential Impact of Pharmacokinetic and Pharmacodynamic Variability on Response to Combination Therapy

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Interindividual variability (IIV) in drug response complicates both fixed‐dose design and individualized therapy. Understanding how pharmacokinetic (PK) and pharmacodynamic (PD) processes jointly shape this variability is essential, particularly in combination therapy, where multiple interacting pathways influence outcomes. This study employed
Kuteesa R. Bisaso, Ronald Kadada Karyaburo, Jackson K. Mukonzo, Ene I. Ette   +3 more
wiley   +1 more source